Topiramate
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Topiramate: From Epilepsy to Trigeminal Nerve Neoplasm
One-Sentence Summary
Topiramate is an antiseizure medication, originally used for generalized tonic-clonic seizures, partial epilepsy and Lennox-Gastaut syndrome. The TxGNN model predicts it may be effective for trigeminal nerve neoplasm, with a score of 99.7%, but there are currently 0 clinical trials and 0 publications supporting this specific prediction. This is a computational prediction only. The data compiled for this report support more strongly a group of related reflex epilepsies, which are discussed below.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Epilepsy with generalized tonic-clonic seizures, partial epilepsy, Lennox-Gastaut syndrome (from the knowledge graph; no approved indication text is available in the US license records) |
| Predicted New Indication | Trigeminal nerve neoplasm |
| TxGNN Prediction Score | 99.70% |
| Evidence Level | L5 |
| US Market Status | Cancelled only (no currently valid licenses in the compiled records) |
| Number of NDAs | 10 (all ANDAs, all listed as cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. From general pharmacology, topiramate is a broad-spectrum antiseizure drug acting through voltage-gated sodium channel blockade, enhancement of GABA-A activity, antagonism of AMPA/kainate glutamate receptors, and weak carbonic anhydrase inhibition.
These mechanisms explain its effect on seizures, but they do not address tumour biology. There is no known mechanistic rationale for treating a neoplasm of the trigeminal nerve. The high score is likely driven by network proximity in the knowledge graph to neurological terms such as trigeminal neuralgia, rather than by a real anti-tumour effect. The prediction should be treated as a hypothesis with no supporting evidence at present.
Other predictions in the same list. The ranked predictions include eight reflex or stimulus-triggered seizure types, which are much more plausible because they fall within the epilepsy spectrum topiramate already treats:
| Predicted Indication | Score | Evidence Level | Comment |
|---|---|---|---|
| Visual epilepsy | 99.28% | L4 | Indirect: general epilepsy reviews only |
| Micturition-induced seizures | 99.21% | L4 | Indirect: general epilepsy reviews only |
| Startle epilepsy | 99.21% | L5 | No trials or literature |
| Thinking seizures | 99.21% | L3 | Cochrane reviews of add-on therapy in drug-resistant partial epilepsy support related seizure types; nothing specific to this condition |
| Audiogenic seizures | 99.21% | L4 | Animal models (DBA/2 mice, GAERS) only |
| Eating seizures | 99.21% | L4 | Retrieved literature mostly concerns eating disorders, a different condition |
| Orgasm-induced seizures | 99.21% | L5 | No trials or literature |
| Reading seizures | 99.09% | L4 | Indirect: IGE and general topiramate papers |
Among these, thinking seizures has the strongest indirect support, because the retrieved Cochrane systematic reviews (for example PMID 24570033 and 31642054) cover topiramate add-on therapy in drug-resistant focal epilepsy. That support carries over from approved indications and is not specific to this condition.
Clinical Trial Evidence
Currently no related clinical trials registered for trigeminal nerve neoplasm. No clinical trials were found for any of the other predicted indications either.
Literature Evidence
Currently no related literature available for trigeminal nerve neoplasm.
For reference, the strongest literature found for the top-ranked epilepsy-related predictions (not specific to the predicted indications) is:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24570033 | 2014 | Systematic review (Cochrane, RCTs) | Cochrane Database Syst Rev | Topiramate add-on therapy in drug-resistant partial epilepsy |
| 31642054 | 2019 | Systematic review (Cochrane) | Cochrane Database Syst Rev | Topiramate add-on therapy in drug-resistant focal epilepsy |
| 37378757 | 2023 | Systematic review / network meta-analysis | J Neurol | Comparison of antiseizure medications in idiopathic generalized epilepsies |
| 39854828 | 2025 | Review / consensus | Epilepsy Behav | Antiseizure medications for Lennox-Gastaut syndrome, including topiramate |
| 34817852 | 2021 | Cochrane review | Cochrane Database Syst Rev | Topiramate for juvenile myoclonic epilepsy |
| 35421622 | 2022 | Review | Seizure | Molecular mechanisms of topiramate and its clinical value in epilepsy |
| 10666508 | 2000 | Preclinical | Eur J Pharmacol | Topiramate antagonized audiogenic seizures in DBA/2 mice and potentiated other anticonvulsants |
| 12581224 | 2003 | Preclinical | Epilepsia | Topiramate effects in GAERS and audiogenic Wistar AS rat models |
US Market Information
All 10 US authorizations in the compiled records are generic applications (ANDAs) with status “cancelled”. No approved indication text is available in these records.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA078235 | Topiramate (Zydus Pharmaceuticals USA) | Tablet, film coated | Not available |
| ANDA090278 | Topiramate (Proficient Rx) | Tablet, film coated | Not available |
| ANDA216683 | Topiramate (Advagen Pharma) | Capsule | Not available |
| ANDA207382 | Topiramate (Zydus Pharmaceuticals USA) | Capsule, extended release | Not available |
| ANDA090162 | Topiramate (A-S Medication Solutions) | Tablet, film coated | Not available |
Safety Considerations
Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the package insert for full safety information.
- Knowledge-graph contraindication signals (not label text): anxiety disorder, neurotic disorder, dysthymic disorder, kidney disease, pyoureter, liver disease, gallbladder disease, diarrheal disease, ocular hypertension, nephrolithiasis (including susceptibility caused by SLC26A1), acute urate nephropathy, acidosis disorder, metabolic acidosis, amnestic disorder, retrograde amnesia.
- Drug interactions: 100 interactions were found in the database query. Examples of Major interactions include metformin, and anticholinergic agents such as hyoscyamine, atropine, scopolamine, glycopyrronium, clidinium, dicyclomine, mepenzolate, methscopolamine, propantheline and trospium. Moderate interactions include pioglitazone, glyburide, morphine, dronabinol, nabilone, phentermine, metoclopramide, phenylbutyric acid and glycerol phenylbutyrate.
- Literature-reported safety observations: a safety review of the double-blind studies (PMID 9706735) noted renal stones among the observed effects, and case reports describe psychotic or manic exacerbation. Pregnancy-related complications are also discussed in the literature (PMID 40716154).
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction, trigeminal nerve neoplasm, has a very high model score but no clinical trials, no literature and no plausible mechanism, so it is a computational prediction only (L5). The related reflex epilepsy predictions are mechanistically plausible but rest on indirect, class-level evidence, and the best of them (thinking seizures) is L3 at most.
To proceed, the following is needed:
- Mechanism of action data and package insert warnings and contraindications (both are currently missing)
- For trigeminal nerve neoplasm: any biological rationale or preclinical data; otherwise deprioritise
- For the reflex epilepsies: indication-specific case series or trials, and consideration of whether these are clinically distinct enough from already-approved epilepsy indications to merit a separate development path
- Clarification of current US marketing status, since all licenses in the compiled records are listed as cancelled
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.